FT-104

FT-104 (4-glutaryloxy-N,N-diisopropyltryptamine) is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT. It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression.[1][2][3][4]

FT-104
Identifiers
  • 5-[[3-[2-[di(propan-2-yl)amino]ethyl]-1H-indol-4-yl]oxy]-5-oxopentanoic acid
PubChem CID
Chemical and physical data
FormulaC21H30N2O
Molar mass326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

See also

References
  1. "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104". 11 August 2022.
  2. Bryson N. Tryptamine Prodrugs. Patent WO 2022/000091
  3. Slassi A, Araujo J. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders. Patent application US 2022/0024956
  4. Slassi A, et al. Hallucinogen-Fatty Acid Combination. Patent WO 2022/246572
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.